AMSBIO launches CellMax™ Cell Pellet Slides

AMSBIO announces the launch of CellMax™ - a new range of high quality, consistent and affordable cell line FFPE slides.

Made using a patent-pending process, CellMax™ Cell Pellet Slides have a highly consistent density and homogeneity across the entire cell pellet block that ensures you get accurate results time after time. Cells are harvested by a proprietary trypsin-free method preserving cell surface antigens and inflicting minimal physical damage that could lead to a loss of biomarkers.

amsbio

CellMax™ slides produce accurate and reproducible results for immunohistochemistry (IHC) providing confidence in antibody performance during IHC analysis. Using CellMax™ both morphological and biological molecules, including protein and nucleic acid targets, are well preserved offering a reference standard for tissue quality during in situ hybridisation (ISH) analysis.

CellMax™ slides are a renewable source of positive and negative controls, derived from 50 tumour cell lines, suitable for assay development and routine analysis. For further information please visit www.amsbio.com/http://www.amsbio.com/cell_line_control_slides.aspx or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / [email protected]. AMSBIO also offer a comprehensive range of tissues slides and antibodies to compliment the new CellMax™ controls.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2017, August 03). AMSBIO launches CellMax™ Cell Pellet Slides. News-Medical. Retrieved on May 24, 2019 from https://www.news-medical.net/news/20150728/AMSBIO-launches-CellMaxe284a2-Cell-Pellet-Slides.aspx.

  • MLA

    AMS Biotechnology. "AMSBIO launches CellMax™ Cell Pellet Slides". News-Medical. 24 May 2019. <https://www.news-medical.net/news/20150728/AMSBIO-launches-CellMaxe284a2-Cell-Pellet-Slides.aspx>.

  • Chicago

    AMS Biotechnology. "AMSBIO launches CellMax™ Cell Pellet Slides". News-Medical. https://www.news-medical.net/news/20150728/AMSBIO-launches-CellMaxe284a2-Cell-Pellet-Slides.aspx. (accessed May 24, 2019).

  • Harvard

    AMS Biotechnology. 2017. AMSBIO launches CellMax™ Cell Pellet Slides. News-Medical, viewed 24 May 2019, https://www.news-medical.net/news/20150728/AMSBIO-launches-CellMaxe284a2-Cell-Pellet-Slides.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
AMSBIO introduces next-generation feeder-free medium for pluripotent stem cell culture